Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03110029
Other study ID # X141114004
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 2015
Est. completion date July 2018

Study information

Verified date June 2019
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test how well efinaconazole solution (Jublia) works to treat toenail fungal infections in patients who wear polish compared to those who do not.


Description:

Topical efinaconazole 10% solution is known to be an efficacious and safe treatment modality for toenail onychomycosis. This study will examine the compatibility of topical efinaconazole and nail polish in patients with distal and lateral subungual onychomycosis (DLSO). It is hypothesized that the treatment of DLSO with efinaconazole 10% solution will not be adversely affected by the application of nail polish.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date July 2018
Est. primary completion date May 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 19 Years to 70 Years
Eligibility Inclusion Criteria:

- Female age 19-70, as 19 is the legal age in Alabama

- DLSO affecting at least 1 great toenail diagnosed with positive potassium hydroxide microscopy and culture of a dermatophyte

- Suitable for application of topical antifungal therapy, in the opinion of the investigator

- Target toenail thickness of 3 mm or less as measured by digital caliper, as thickness greater than 3 mm may allow inclusion of patient with severe onychomycosis, and this was the criteria used in the pivotal trial using topical efinaconazole for onychomycosis

- Women of childbearing potential will be required to use birth control and a negative urine pregnancy test must be documented prior to initiating treatment

Exclusion Criteria:

- History of immunosuppression or concurrent use of immunosuppressant drugs

- History of uncontrolled diabetes mellitus

- History of psoriasis or any other condition that might interfere with the toenail evaluation

- Three or more dermatophytomas (streaks) on the target nail

- Severe DLSO of the target nail

- Patients who cannot refrain from wearing gel or plastic based polishes that are used in salons and that require curing

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Efinaconazole 10% Topical Application Solution [JUBLIA]
Topical efinaconazole 10% solution (Jublia)
Other:
Application of Nail Polish
Application of Nail Polish

Locations

Country Name City State
United States The Kirklin Clinic Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Nail Polish Disruption Using the Likert Scale Patients will answer the following question:
Which will be answered using a Likert scale where 0 represents no alteration in polish and 10 represents complete destruction of the polish:
Is the quality of your polish diminished with use of Jublia?
52 weeks
Secondary Percentage of Disease Improvement Using Onychomycosis Severity Index (OSI) Using 3rd party blinding, DLSO was assessed at baseline and at every subsequent visit using the onychomycosis severity index (OSI), measuring percent of the target nail involved, and grading the infection from mild to moderate to severe. The range for OSI is 0-20 with 20 indicating severe nails disease. Nail growth was measured at each visit. Fungal testing was done at screening, 3 months, 7 months, end of treatment (48 weeks), and end of study (52 weeks). Clinical and mycologic cure was evaluated at week 52. 52 week
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05110638 - Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis Phase 1
Completed NCT05260450 - Laser Treatment of Toenail Onychomycosis With a 1064 nm Nd:YAG-laser N/A
Completed NCT03382717 - Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis N/A
Not yet recruiting NCT06417983 - Topical Application of Essential Oils to Treat Onchomycosis
Withdrawn NCT03094468 - Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis Phase 3
Recruiting NCT05674747 - Pilot Study of Swift Microwave Device for Onychomycosis Phase 1/Phase 2
Recruiting NCT06006455 - Effect of the Erchonia® LunulaLaserâ„¢ for the Treatment of Toenail Onychomycosis N/A
Not yet recruiting NCT03098342 - Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment N/A
Completed NCT03216200 - Early Feasibility Study to Evaluate the Efficacy of the RenewalNailâ„¢ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail) N/A
Recruiting NCT04042857 - Safety and Efficacy of Next Science Gel on Toenail Fungus N/A
Active, not recruiting NCT05135910 - To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis Phase 2
Active, not recruiting NCT05139888 - Light Therapy for Onychomycosis Study N/A
Completed NCT04961684 - Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis N/A
Completed NCT03141840 - Clinical Trial of Topical ABL01 Treatment of Onychomycosis N/A
Recruiting NCT04084782 - An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection (Onychomycosis) During Treatment With Scholl Fungal Nail.
Withdrawn NCT03066336 - A Study to See if Low Level Laser Light Can Help to Treat Toenail Fungus N/A